Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shang Yi

Showing results (301-310 of 357) with videos related to

Pageof 36
Sort By:
Jac-Antimicrobial Resistance|May 13, 2026
Clinical implications of cefoperazone-sulbactam MIC values in <i>Pseudomonas aeruginosa</i> bloodstream infections: a multicentre studyShian-Sen Shie, Ting-Shu Wu, Feng-Yee Chang, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
British Journal of Haematology|December 23, 2016
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myelomaNoopur S Raje, Philippe Moreau, Evangelos Terpos, et al.
Infectious Diseases and Therapy|July 21, 2022
Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli BacteremiaShang-Yi Lin, Po-Liang Lu, Ting-Shu Wu, et al.
British Journal of Haematology|March 29, 2019
Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort studyJia-Hau Liu, Xiu-Wen Liao, Chien-Hung Chen, et al.
Cell Reports|February 3, 2015
Functional consequences of 17q21.31/WNT3-WNT9B amplification in hPSCs with respect to neural differentiationChun-Ting Lee, Raphael M Bendriem, Abigail A Kindberg, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 12, 2024
Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatmentTsung-Ta Chiang, Ming-Hsien Chiang, Hung-Jen Tang, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 18, 2025
High co-infection burden and ICU-specific pathogen profiles in pediatric Candida albicans respiratory infections: a large-scale tNGS analysisYa Huang, Huideng Zhou, Jiangyang Zhao, et al.
European Journal of Human Genetics : EJHG|August 20, 2009
Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosisMing-Wei Lin, Ding-Dar Lee, Tze-Tze Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2022
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup AnalysisKazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, et al.
Pageof 36

Showing results (301-310 of 357) with videos related to

Sort By:
Pageof 36
Jac-Antimicrobial Resistance|May 13, 2026
Clinical implications of cefoperazone-sulbactam MIC values in <i>Pseudomonas aeruginosa</i> bloodstream infections: a multicentre studyShian-Sen Shie, Ting-Shu Wu, Feng-Yee Chang, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
British Journal of Haematology|December 23, 2016
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myelomaNoopur S Raje, Philippe Moreau, Evangelos Terpos, et al.
Infectious Diseases and Therapy|July 21, 2022
Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli BacteremiaShang-Yi Lin, Po-Liang Lu, Ting-Shu Wu, et al.
British Journal of Haematology|March 29, 2019
Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort studyJia-Hau Liu, Xiu-Wen Liao, Chien-Hung Chen, et al.
Cell Reports|February 3, 2015
Functional consequences of 17q21.31/WNT3-WNT9B amplification in hPSCs with respect to neural differentiationChun-Ting Lee, Raphael M Bendriem, Abigail A Kindberg, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 12, 2024
Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatmentTsung-Ta Chiang, Ming-Hsien Chiang, Hung-Jen Tang, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 18, 2025
High co-infection burden and ICU-specific pathogen profiles in pediatric Candida albicans respiratory infections: a large-scale tNGS analysisYa Huang, Huideng Zhou, Jiangyang Zhao, et al.
European Journal of Human Genetics : EJHG|August 20, 2009
Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosisMing-Wei Lin, Ding-Dar Lee, Tze-Tze Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2022
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup AnalysisKazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, et al.
Pageof 36